CRSP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CRSP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
CRISPR Therapeutics AG's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $2,083.9 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.
Total Stockholders Equity is used to calculate Book Value per Share. CRISPR Therapeutics AG's Book Value per Share for the quarter that ended in Mar. 2024 was $24.56. The ratio of a company's debt over equity can be used to measure how leveraged this company is. CRISPR Therapeutics AG's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.11.
The historical data trend for CRISPR Therapeutics AG's Total Stockholders Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRISPR Therapeutics AG Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Total Stockholders Equity | Get a 7-Day Free Trial | 939.43 | 1,664.23 | 2,399.46 | 1,875.48 | 1,882.80 |
CRISPR Therapeutics AG Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Total Stockholders Equity | Get a 7-Day Free Trial | 1,854.90 | 1,816.03 | 1,727.79 | 1,882.80 | 2,083.94 |
CRISPR Therapeutics AG (NAS:CRSP) Total Stockholders Equity Explanation
1. Total Stockholders Equity is used to calculate Book Value per Share.
CRISPR Therapeutics AG's Book Value per Share for the quarter that ended in Mar. 2024 is
Book Value per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (2083.936 | - | 0) | / | 84.8376 | |
= | 24.56 |
2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.
CRISPR Therapeutics AG's Debt-to-Equity for the quarter that ended in Mar. 2024 is
Debt-to-Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (15.992 | + | 218.935) | / | 2083.936 | |
= | 0.11 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of CRISPR Therapeutics AG's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Samarth Kulkarni | officer: Chief Business Officer | C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139 |
Raju Prasad | officer: Chief Financial Officer | CRISPR THERAPEUTICS, INC., 105 W FIRST STREET, BOSTON MA 02127 |
Phuong Khanh Morrow | officer: Chief Medical Officer | C/O CRISPR THERAPEUTICS, 610 MAIN STREET, CAMBRIDGE MA 02139 |
Maria Fardis | director | C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085 |
Brendan Smith | officer: Chief Financial Officer | 29 HARTWELL AVENUE, LEXINGTON MA 02421 |
Michael John Tomsicek | officer: Chief Financial Officer | 28 OVERLOOK DRIVE, BEDFORD MA 01730 |
Bolzon Bradley J Phd | director | ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
Rodger Novak | director, officer: Chief Executive Officer | C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139 |
Harold Edward Fleming | director | C/O CRISPR THERAPEUTICS AG, 610 MAIN STREET, CAMBRIDGE MA 02139 |
Lawrence Otto Klein | officer: Chief Business Officer | C/O CRISPR THERAPEUTICS AG, 610 MAIN STREET 7TH FLOOR, CAMBRIDGE MA 02139 |
James R. Kasinger | officer: General Counsel and Secretary | C/O CRISPR THERAPEUTICS, INC., 610 MAIN STREET, CAMBRIDGE MA 02139 |
Tony W Ho | officer: See Remarks | CRISPR THERAPEUTICS AG, 610 MAIN STREET, CAMBRIDGE MA 02139 |
Douglas A Treco | director | 87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140 |
Pablo J Cagnoni | director | ONYX PHARMACEUTICALS, INC., 249 E. GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
Katherine A High | director | 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104 |
From GuruFocus
By Marketwired • 09-07-2023
By Marketwired • 09-27-2023
By Value_Insider Value_Insider • 12-01-2022
By sperokesalga sperokesalga • 06-13-2023
By GuruFocus Research • 11-16-2023
By sperokesalga sperokesalga • 02-21-2023
By sperokesalga sperokesalga • 05-02-2023
By Stock market mentor Stock market mentor • 02-08-2023
By Value_Insider Value_Insider • 12-12-2022
By sperokesalga sperokesalga • 03-29-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.